Key Points
- On Feb. 9, Insmed CEO William Lewis sold 13,396 shares at an average price of $147.79 for about $1.98M, reducing his stake to 301,185 shares (a 4.26% ownership decline, valued at roughly $44.51M).
- That sale is part of a recent string of insider disposals — Lewis sold a total of 66,694 shares since Dec. 18, generating approximately $10.87M in proceeds across the transactions.
- Insmed stock opened at $148.43 and sits below its 50‑day and 200‑day averages ($171.34 and $161.28); analysts have an average rating of Buy with an average price target of $204.24.
Insmed, Inc. (NASDAQ:INSM - Get Free Report) CEO William Lewis sold 13,396 shares of the stock in a transaction that occurred on Monday, February 9th. The shares were sold at an average price of $147.79, for a total value of $1,979,794.84. Following the completion of the sale, the chief executive officer directly owned 301,185 shares of the company's stock, valued at $44,512,131.15. This represents a 4.26% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website.
William Lewis also recently made the following trade(s):
- On Tuesday, February 3rd, William Lewis sold 3,009 shares of Insmed stock. The shares were sold at an average price of $156.34, for a total transaction of $470,427.06.
- On Tuesday, January 20th, William Lewis sold 10,699 shares of Insmed stock. The stock was sold at an average price of $158.93, for a total transaction of $1,700,392.07.
- On Monday, January 12th, William Lewis sold 19,215 shares of Insmed stock. The stock was sold at an average price of $169.00, for a total transaction of $3,247,335.00.
- On Thursday, January 8th, William Lewis sold 3,223 shares of Insmed stock. The shares were sold at an average price of $174.17, for a total transaction of $561,349.91.
- On Wednesday, January 7th, William Lewis sold 2,357 shares of Insmed stock. The shares were sold at an average price of $175.07, for a total transaction of $412,639.99.
- On Tuesday, January 6th, William Lewis sold 4,096 shares of Insmed stock. The shares were sold at an average price of $173.33, for a total value of $709,959.68.
- On Thursday, December 18th, William Lewis sold 10,699 shares of Insmed stock. The shares were sold at an average price of $166.97, for a total value of $1,786,412.03.
Insmed Price Performance
Shares of INSM stock opened at $148.43 on Thursday. The stock has a 50 day moving average of $171.34 and a two-hundred day moving average of $161.28. The company has a current ratio of 4.63, a quick ratio of 4.34 and a debt-to-equity ratio of 0.59. Insmed, Inc. has a 12 month low of $60.40 and a 12 month high of $212.75. The company has a market capitalization of $31.66 billion, a P/E ratio of -23.98 and a beta of 1.11.
Wall Street Analysts Forecast Growth
A number of equities research analysts have weighed in on the stock. Roth Mkm upgraded shares of Insmed to a "strong-buy" rating in a research note on Friday, January 23rd. TD Cowen set a $241.00 target price on shares of Insmed in a research note on Thursday, December 18th. Wolfe Research set a $167.00 price target on shares of Insmed and gave the stock an "outperform" rating in a research report on Thursday, December 18th. Truist Financial set a $205.00 price target on shares of Insmed in a research note on Monday, January 12th. Finally, Citigroup reaffirmed an "outperform" rating on shares of Insmed in a report on Thursday, December 18th. Three equities research analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company's stock. According to MarketBeat, the stock has an average rating of "Buy" and an average price target of $204.24.
View Our Latest Stock Analysis on INSM
Institutional Investors Weigh In On Insmed
A number of hedge funds have recently made changes to their positions in INSM. CIBC Private Wealth Group LLC boosted its position in Insmed by 42.1% in the third quarter. CIBC Private Wealth Group LLC now owns 179 shares of the biopharmaceutical company's stock valued at $26,000 after buying an additional 53 shares in the last quarter. CoreCap Advisors LLC bought a new position in shares of Insmed in the fourth quarter valued at approximately $27,000. Stone House Investment Management LLC bought a new position in shares of Insmed in the third quarter valued at approximately $29,000. SBI Securities Co. Ltd. boosted its holdings in shares of Insmed by 404.9% in the 3rd quarter. SBI Securities Co. Ltd. now owns 207 shares of the biopharmaceutical company's stock worth $30,000 after acquiring an additional 166 shares in the last quarter. Finally, GraniteShares Advisors LLC acquired a new position in shares of Insmed in the 4th quarter worth approximately $30,000.
About Insmed
(
Get Free Report)
Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing therapies for patients with rare and serious diseases, with a particular emphasis on difficult-to-treat pulmonary infections. Headquartered in Bridgewater, New Jersey, the company concentrates its research and development efforts on targeted drug delivery technologies and novel formulations intended to improve clinical outcomes for patients who have limited treatment options.
The company's principal marketed product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled liposomal formulation of the antibiotic amikacin that is approved by the U.S.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
